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The British mesothelioma register contains all deaths from 1968 to 2001 where mesothelioma was mentioned on the death
certificate. These data were used to predict the future burden of mesothelioma mortality in Great Britain. Poisson regression analysis
was used to model male mesothelioma deaths from 1968 to 2001 as a function of the rise and fall of asbestos exposure during the
20th century, and hence to predict numbers of male deaths in the years 2002–2050. The annual number of mesothelioma deaths in
Great Britain has risen increasingly rapidly from 153 deaths in 1968 to 1848 in 2001 and, using our preferred model, is predicted to
peak at around 1950 to 2450 deaths per year between 2011 and 2015. Following this peak, the number of deaths is expected to
decline rapidly. The eventual death rate will depend on the background level and any residual asbestos exposure. Between 1968 and
2050, there will have been approximately 90 000 deaths from mesothelioma in Great Britain, 65 000 of which will occur after 2001.
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Mesothelioma is a formerly rare cancer that principally affects the
pleura and the peritoneum (Greenberg and Lloyd Davies, 1974)
and is almost always caused by asbestos exposure. The disease is
rapidly fatal, most of those affected dying within a year of
diagnosis (Peto et al, 1995). There is a long latent period between
first exposure to asbestos and diagnosis of mesothelioma that is
seldom less than 15 years and often exceeds 60 years (Bianchi et al,
1997). In all, 85% of deaths are among men, and the risk is highest
in occupations with substantial exposure to asbestos (McElvenny
et al, 2005).
Previous predictions of future numbers of mesothelioma deaths
in Britain were based on observed male deaths between 1968 and
1991 (Peto et al, 1995; Hodgson et al, 1997) and were derived from
a simple birth cohort model in which mesothelioma risk was
related independently to age and to date of birth. These analyses
suggested that male mesothelioma deaths would peak at about
2700– 3300 deaths around 2020. The data have conformed to this
model well up to 1991, but from the 1990s show a departure from
fit for some of the later cohorts (Figure 1A and B). The slower
increase with age for mesothelioma death rates in the 1990s implies
that the simple age–cohort model is not reliable. We fitted the
age–cohort model as confirmation of these observations, but our
main models related current mortality to past asbestos exposure
levels and did not assume the same age distribution of mortality in
different birth cohorts.
MATERIALS AND METHODS
The mesothelioma register is described in detail elsewhere
(McElvenny et al, 2005). Briefly, deaths occurring in England,
Scotland and Wales, where mesothelioma was mentioned on the
death certificate, are notified annually to the Health and Safety
Executive by the Office for National Statistics and the General
Register Office for Scotland. Originally, this was done manually as
part of the coding of causes of death, but since 1992 (1996 in
Scotland), the computerised national mortality database has been
scanned. Checks for completeness include searching deaths in
England and Wales for alternative spellings of mesothelioma and
flagging cancer registrations with a morphology code consistent
with mesothelioma for death notification at the National Health
Service Central Registers in Edinburgh and Southport.
Details of the analysis, which was based on deaths in men aged
20–89 years between 1968 and 2001, are given in Appendix A1.
The model parameters were estimated iteratively, and
the deviance (based on observed and expected numbers aggregated
over 5-year groups by age, date of birth and year of death)
was used to assess overall goodness of fit. Two of the model
parameters, k (the power of time defining the increase in risk
after exposure) and H (the half-life for clearance of asbestos from
the lung), are closely correlated and cannot be independently
estimated. The effect of reducing the half-life is to increase the
best-fit value of k, but the fit of the model is affected only slightly.
Since fitting the model with both H and k is unstable, we used two
versions of the model, one with (effectively) no clearance
(H¼ 1000 years) and the other with a clearance half-life of 15
years – a value suggested from the modelling of mortality of the
Wittenoom workforce (Berry, 1991).
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The adequacy of the model was tested by examining deviance
residuals and by comparing observed and fitted numbers
of mesothelioma deaths. The uncertainty of the estimate
was quantified by calculating an approximate 95% confidence
(CI) interval for the peak in predicted future number of
mesothelioma deaths and the year in which this peak was expected
to occur. Our estimate of the predicted peak was scaled to include
mesothelioma deaths in men aged 90 years or older, and deaths
among women.
Mesothelioma mortality is very low up to 20 years after
first asbestos exposure even among heavily exposed workers
(Peto et al, 1982), so death rates up to 2001 give virtually no
information on exposures in the previous 20 years. The level
and timing of the predicted peak in mortality are
virtually unaffected by exposure since 1980, but for longer-term
prediction recent exposures become increasingly relevant,
and some assumption must be made about asbestos exposure
since the 1970s. An assessment of current exposure levels
for a recent HSE Regulatory Impact Assessment (HSE,
2002) suggested that population exposure in the 2000 was
around 4% of the peak value reached in the 1960s. For the present
projections, we assumed a continuing decline in asbestos exposure,
from 4% of the peak level in 2000 to 2% by 2010 and 0.75%
by 2050.
RESULTS
The annual number of mesothelioma deaths in Great Britain has
risen increasingly rapidly by about 12-fold from 1968 (the first year
in which ascertainment is believed to be complete) to 2001
(Figure 2). The mesothelioma death rate in males has continued
to increase in older age groups, but has decreased among younger
men in recent years (Figure 3). In 2001, there were 1579 male deaths,
85% of the total, the majority being at ages 60–79 years, with
relatively few aged less than 50 years. Less than 1% of deaths in men
have occurred at age 90 or older, but the number is likely to increase
substantially over time. Men born around 1940 have suffered higher
death rates than any previous or subsequent birth cohort (Figures
1A and B), and they will not reach 90 years of age until 2030.
Parameter values estimated from the two versions of the Poisson
regression model are shown in the Table 1. The two versions of the
model produced effectively equivalent fits overall, and showed very
similar patterns of residuals. This is illustrated (for the nonclear-
ance model) in Figures 4A–C which show plots of fitted and
observed deaths by year of birth, age and year of death. These
show close agreement. A two-dimensional array (not shown) of
deviance residuals by 5-year age and year of birth groupings also
showed an unbiased pattern with no strong clustering of residuals
of the same sign. While the fit of the clearance and nonclearance
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Figure 1 (A) Mesothelioma death rates by 5-year cohort and age group for males born 1878–1937 (note: The earlier cohorts are to the lower right of
the chart). (B) Mesothelioma death rates by 5-year cohort and age group for males born 1938–1982 (note: The earlier cohorts are to the upper left of the
chart).
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versions of the model to past data were equivalent, their
predictions of future mortality were different. Under the
nonclearance model, the annual number of mesothelioma deaths
in men aged below 90 years is predicted to reach a peak of 1846
deaths (95% CI 1650– 2100) in 2013 (95% CI 2011–2015). The
clearance model predicts a peak of 1983 deaths (95% CI 1835–
2233) in 2011 (95% CI 2009–2013). As more data accumulate on
the pattern of reduced mortality related to exposure levels after the
mid-1960s peak, it may be possible to estimate the parameters k
and H separately.
Allowing for deaths occurring in men aged 90 or over, the
estimated peak among males is 1857. Assuming a linear relation-
ship between annual numbers of male M and female F
mesothelioma deaths (F¼ 22.9þ 0.136M; R2¼ 0.95), the maximum
number of female deaths was estimated to be 276, giving a
predicted total of 2133 mesothelioma deaths (95% CI 1950– 2450)
at the peak of the epidemic. The total number of mesothelioma
deaths to 2050 is predicted to be around 90 000, with 65 000 of
these occurring from 2002 onwards.
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Figure 2 Mesothelioma deaths by sex and year.
Table 1 Estimated parameter values from optimal Poisson’s regression model
Parameter
Estimates for non
clearance model (half life¼ 1000 years)
Estimates for model
with clearance half life of 15 years
Power of time since first exposure, k 2.6 4.1
Year of exposure maximum 1967 1962
Diagnostic trend (percentage decrease in missed cases per year), DxT 5 2
Relative exposure potential for age group (years)
0–4 0.00 0.00
5–15 0.03 0.07
16–19 0.21 1.18
20–29 1.00 (baseline) 1.00 (baseline)
30–39 1.24 1.95
40–49 1.11 1.02
50–59 0.00 0.08
60–64 0.00 0.00
65+ 0.00 0.00
Change in exposure index (percentage per year) in peak year7X years % change % change
45 29 30
35 6 8
25 11 11
15 9 9
5 5 10
0 (peak year) 0 0
+5 14 17
+15 39 4
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Figure 3 Average annual male mesothelioma death rates per million by
age and time period.
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DISCUSSION
The age–cohort model was fitted (residual deviance 121.5 on 72
degrees of freedom) and confirmed the observed departure of the
data from that model by providing a significantly worse fit than
our preferred model (residual deviance 235.6 on 182 degrees of
freedom). The existence of two versions of the model (one with
clearance and the other with no clearance) with equivalent overall
fits but with different future implications raises the obvious
question as to which is closest to the truth.
One way of assessing which model is the most realistic
is to match the implied exposure patterns from each of the
models with the actual pattern of asbestos imports, taking account
of the difference between fibre types. Figure 5A shows the
fitted exposure index for the nonclearance model together
with the best approximating linear combination of the three
fibre-specific import profiles, and Figure 5B shows this informa-
tion for the lung clearance model (chrysotile had zero weight
in both). It is evident that overall approximation is less good
for the clearance than for the nonclearance exposure index.
Although this argument is not definitive, we interpret the better
agreement of imports with the exposure profile associated with
the nonclearance model as justifying a modest preference
for this model in developing our current projections. This
preference is reinforced by the fact that the observed 2001 total
number of mesothelioma deaths is a more extreme outlier in
relation to the clearance model (1563 observed vs 1463 expected,
P¼ 0.0022) than in relation to the nonclearance model (1488
expected, P¼ 0.0143).
Our assumption that exposure in 2000 was 4% of the peak level
hardly affects the predicted peak in mesothelioma mortality. It
does, however, influence the predicted number of cases following
the peak. Thus, the total burden of mesothelioma mortality to 2050
remains very uncertain. The estimated power of time since first
exposure of 2.6 is in the range expected on the basis of fits of
similar models to cohort data, providing a measure of support for
the application of the model at that population level. The
diagnostic trend, a decrease of 5% per year in the proportion of
cases that are undiagnosed, implies that in 1968 about 90% of cases
were diagnosed. This parameter improves the fit but has virtually
no influence on the projections.
The model was fitted by minimising the total deviance. Recent
birth cohorts have fewer mesothelioma deaths, so the fitted model
is dominated by earlier cohorts with longer follow-up. The 1920–
1924 cohort has the most deaths. Residuals for the most recent
cohorts therefore provide an indicator of predictive reliability.
Figures 4A and D show observed and fitted deaths by year of birth,
with some divergence for the most recent births (Figure 4D). From
1965 onwards there are eight deaths compared to a fitted value of
3.5, a borderline significant excess (P¼ 0.054). However, the fitted
model does not include an allowance for a background rate of
mesothelioma. If there were, as widely assumed, around 1 –2% of
male mesothelioma deaths not due to asbestos exposure, this
equates to around 50 male deaths annually in Great Britain. On this
basis, around four deaths would be expected among those not
exposed to asbestos and born from 1965 onwards, bringing
observed and fitted into good agreement. As data accumulates in
these more recently born groups, it will be important to make
explicit allowance in the model for the possibility of a background
rate. In terms of projecting the timing and level of peak mortality,
however, the numbers generated by this background rate can be
ignored.
Predictions of the future number of mesothelioma cases have
been attempted in other countries. For example, in Denmark, the
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Figure 4 (A) Observed and fitted deaths by year of birth. (B) Observed and fitted deaths by age. (C) Observed and fitted mesothelioma deaths by year
of death, with derived exposure index. (D) Number of observed and fitted mesothelioma deaths for 1955–1980 yearly birth cohorts.
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1912 cases of malignant mesothelioma reported to the
Danish cancer registry between 1943 and 1993 were used to
predict a peak incidence of 93 cases among men born before
1955 to around the year 2015 (Kjaergaard, 2000). In the United
States, using mesothelioma incidence data from the Surveillance,
Epidemiology and End Results programme, it has been estimated
that there will be a peak around the years 2000 to 2004 of
approximately 2000 cases and a return to background incidence
by 2055 (Price and Ware, 2004). In Australia, the incidence of
mesothelioma is expected to peak around 700 cases per year
in 2010 (Leigh and Driscoll, 2003). In Sweden, the preventive
measures of the mid-1970s can probably not be evaluated
with reasonable precision until around 2005 (Jarvholm
et al, 1999). In the Netherlands, it has been predicted that pleural
mesothelioma will peak around the year 2028, with up to 900 cases
per year (Segura et al, 2003). In France, the number of deaths is
predicted to reach a peak at about 2200 per year some time
after 2020 (Ilg et al, 1998). Based on combined data from
Britain, France, Germany, Italy, the Netherlands, Switzerland
and Hungary, it has been suggested that the number of men dying
from mesothelioma will almost double over the next 20 years,
peaking at about 90 000 cases around 2018 (Peto et al, 1999).
These projections – like the earlier British projections (Peto et al,
1995) – were based on a simple age and birth cohort model.
More recent death rates in three of these countries (France,
Germany and Italy) are lower than were predicted, and the timing
and level of the peak of Europe-wide mesothelioma deaths may
prove to be earlier and lower, respectively, than previous
projections suggested.
CONCLUSIONS
The data for 2001 showed around 1850 mesothelioma
deaths among males and females in Great Britain. Using a
statistical modelling approach, mesothelioma mortality in
Great Britain is predicted to peak at around 1950–2450 deaths
per year some time between 2011 and 2015. Around 90 000 deaths
are predicted to occur by 2050, with 65 000 of these occurring from
2002 onwards.
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Figure 5 (A) Fitted import index for nonclearance model with best approximating weighting of actual import series (amositeþ 0.7 crocidolite.
(B) Fitted import index for clearance model with best approximating weighting of actual import series (amositeþ 2.2 crocidolite).
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Appendix A1
THE POISSON REGRESSION MODEL
Introduction Mesothelioma mortality rises rapidly with increas-
ing time since first asbestos exposure but is independent of age
(Peto et al, 1982). These observations can be explained by a dose–
response model in which the increase in subsequent mesothelioma
risk caused by each episode of asbestos exposure is proportional to
the cumulative dose inhaled and to the second or third power of
time since the exposure (Peto, 1979). The fit is slightly improved
up to 20 years after first exposure by assuming a lag of 10 years
before mortality begins to increase (Peto et al, 1982). This
relationship has been used as a basis for risk assessment and
regulation by several agencies, including the United Kingdom
(Doll and Peto, 1985) and the United States of America (Health
Effects Institute, 1991). We have adapted the model to find an
asbestos exposure distribution by year and by age that generates
predicted mesothelioma deaths by year and age close to the
observed pattern from 1968 to 2001, and hence to predict future
rates. The model was developed to predict an individual’s risk
from his level of asbestos exposure in each previous year, but we
have used it to predict the death rate in each birth cohort of British
men as a function of their average exposure in each year.
Model formulation Under the dose–response model for
mesothelioma developed by the Health Effects Institute (HEI)
(Health Effects Institute, 1991), an individual’s additional me-
sothelioma risk caused by each brief exposure to asbestos is
proportional to the increase in cumulative exposure D multiplied
by the second or third power of time t since the exposure lagged by
10 years:
R / Dðt  10Þk
As the predicted risk after a given interval is directly proportional
to the exposure D, the HEI model can also be applied at the
population level to death rates in each birth cohort, replacing an
individual’s asbestos exposure D in a given period by the
corresponding average collective dose.
The following additional assumptions were incorporated in the
model we have fitted:
(i) Average asbestos exposure to the male population of Great
Britain in each year is summarised by a single estimate, but
exposure also varies with age. This age dependence for
exposure is assumed to be the same in all past and future
periods.
(ii) A trend in the completeness of mesothelioma diagnosis over
time is included.
(iii) A half-life of 1000 years was arbitrarily assumed for the
proportion of fibres remaining in the lung. (The shorter half-
life of 15 years increased the estimated power k but gave
similar goodness of fit and predictions.)
The mesothelioma death rate for men aged A in year T was
approximated by the sum of the risks due to exposure in all
previous years of their lifetime, excluding the most recent 10 years.
For each of these individual years, the contribution to the
predicted death rate was calculated as the product of the
appropriate age-specific exposure factor, the overall population
exposure index for that year and the lagged time interval to year T
raised to the power k. The predicted number of mesothelioma
deaths at age A in year T is then proportional to the sum of these
risk contributions multiplied by the estimated proportion of
mesothelioma cases in year T that were diagnosed, and the total
population aged A in year T (i.e. the person-years for age A and
year T). Rescaling so that the total fitted number of mesothelioma
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deaths in the period 1968– 2001 is equal to the total observed
number in the same period gives the predicted number of deaths
for persons aged A in year T. The model can be represented
mathematically as follows:
FA;T ¼
PA1
l¼0 WAlDTl l þ 1  Lf gk0:51=H
h i
DxTPA;TM
P
A;T
PA1
l¼0 WAlDTl l þ 1  Lf gk0:51=H
h i
DxTPA;T
where FA,T is the number of deaths at age A in year T; WA is the
age-specific exposure potential at age A; DT is the overall
population exposure in year T; DxT is the proportion of
mesothelioma deaths in year T that are recorded; L is the lag
period in years between exposure and disease occurrence; H is the
half-life in years for asbestos clearance from the lungs; k is the
exponent of time representing the increase of risk with increase of
time since exposure; PA,T is the person-years at risk for age A in
year T; M is the total observed mesothelioma deaths 1968–2001;
the content of {} is set to zero when negative; the summations
indexed by l represent the cumulative effect at age A of the
exposures at earlier ages; and l indexes years lagged from the risk
year.
Details of model parameters Age-specific exposure potential WA
was defined by assigning nine parameters to the age groups 0– 4,
5–15, 16–19, 20– 29, 30–39, 40–49, 50–59, 60– 64 and 65þ years.
Age group 20– 29 years was chosen as the baseline category.
General exposure level in a given year DT is the average ‘effective
carcinogenic dose’ in the breathing zone of men aged 20–29 years .
If crocidolite were (for example) five times more dangerous than
amosite, its contribution to DT per unit dose would be five times
greater.
The exposure distribution was defined by growth and decline
rates for years in multiples of 10 before and after the maximum
exposure year (in which exposure growth/decline is zero). Growth
rates for years intermediate between the 10-yearly values were
determined by linear interpolation. Owing to the long latency of
mesothelioma, exposures after 1980 could not be estimated. Based
on an assessment of the current distribution of exposures (set out
in detail in a recent HSE Regulatory Impact Assessment – HSE,
2002), it was assumed that the total asbestos exposure to the
population in 2000 would be approximately 4% of the peak value.
Using predicted building demolition rates from 2001 to 2050, it
was estimated that exposure would be at 2% of the maximum by
2010 and 0.75% of the maximum by 2050.
Diagnosis was assumed to be essentially complete (98%) in 1997.
The diagnostic trend DxT was parameterised as the annual
percentage increase in the number of missed cases working
backwards in time from this year.
Clearance of fibres from the lung was assumed to follow an
exponential decline parameterised by its half-life H.
Testing of model adequacy and uncertainty The adequacy of the
final model was assessed by examining deviance residuals and
comparing plots of observed and expected mesothelioma deaths.
Approximate 95% CIs for the level and the timing of the predicted
peak in mesothelioma deaths were calculated by adjusting model
parameters to produce a lower/earlier peak and a higher/later
peak, corresponding to a change in the deviance from the optimal
model equivalent to the 5% critical value of the w2 distribution on
the number of degrees of freedom in the model. The resultant
ranges are roughly equivalent to 95% CIs, but are slightly
narrower, since they cannot take account of uncertainties in the
mathematical formulation of the model.
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